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Abstract The objective of this work was to study the efficacy
and safety of pre-emptive rituximab (RTX) in a series of
patients with severe relapsing granulomatosis with polyangi-
itis (GPA). GPA is a systemic vasculitis with a high relapse
rate despite successful remission induction. Drug toxicity with
repeated induction treatments and long-standing immunosup-
pression poses a problem. Based on the findings in reports on
RTX for rheumatoid arthritis, we treated patients with severe
relapsing GPAwith pre-emptive RTX, 1,000mg 2weeks apart
every 6 months, aiming at achieving sustainable remission.
All patients at one centre with relapsing GPA in spite of
traditional maintenance treatment, who had received more
than or equal to three cycles of RTX as regularly repeated
pre-emptive maintenance therapy every 6 months, were in-
cluded in this retrospective study. Information on disease
manifestations and activity, treatments, lab parameters and
adverse events was extracted from the medical files. Of the
12 included patients, all with a positive proteinase 3–anti-
neutrophil cytoplasmic antibodies, generalised disease and a
median disease duration of 35 months (21–270), 92 % (11/12)
achieved sustainable remission during a median follow-up
time of 32 months (range 21–111) from first RTX treatment.
Concomitant immunosuppressants were reduced. Infections
were the most common adverse events, but infections were an
issue also before the start of RTX. RTX administered every
6 months seems to be an effective maintenance treatment in a
population with severe, relapsing long-standing GPA. Granu-
lomatous as well as vasculiticmanifestations responded equal-
ly well. Infections are a problem in this patient group but no
new safety problems were identified.
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Introduction
Granulomatosis with polyangiitis (GPA) is a systemic necro-
tizing vasculitis, typically engaging the upper airways, kid-
neys and lungs and often associated with circulating anti-
neutrophil cytoplasmic antibodies (ANCA) directed against
proteinase 3 (PR3). The well-established standard treatment
for remission induction in GPA has been cyclophosphamide
(CY), in combination with corticosteroids (CS) [1, 2]. This
treatment regimen, introduced in the 1970s, has dramatically
improved the outcome for GPA patients but with a risk of
considerable side effects, including infections, sterility and
bladder cancer [3]. Maintenance treatment is usually given
with methotrexate (MTX), azathioprine (AZA) or mycophe-
nolate mofetil (MMF), but as at least 50 % of patients have
one or several relapses, repeated induction treatment is often
necessary with the risk of high cumulative doses of CY [4, 5].
Recently, rituximab (RTX) has been approved by the FDA
and the European Medicines Agency (EMA) for induction
treatment of GPA and microscopic polyangiitis (MPA) in
combination with CS, using the lymphoma protocol of
375 mg/m2 once weekly for 4 weeks. However, the efficacy
and safety of repeated RTX courses as maintenance treatment
has not yet been established.
B lymphocytes play an important role in many autoim-
mune diseases, including GPA [6–8]. Induction therapy with
RTX has reported successful remission of GPA in two
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randomised trials comparing CYand RTX [9, 10], but relapses
after RTX-induced remission still occurred in a significant
number of patients. A retrospective study of 59 patients with
refractory GPA [11] described successful induction of remis-
sion, response or stabilisation of disease in 67 % of patients
given two to three RTX treatments, but 33 % of patients were
refractory to treatment and this failure to respond was mainly
due to the persistence of granulomatous manifestations. Also,
the relapse rate during amedian follow-up time of 13.5months
was 44 %. Several other studies report successful remission
induction with RTX also in previously refractory disease
[12–14]. Two smaller retrospective studies have addressed
RTX as maintenance therapy after achieving remission [15,
16], both reporting successful results with less frequent re-
lapses. Just recently, two larger retrospective studies have
been published reporting RTX as remission and/or mainte-
nance therapy [17, 18]. Both these studies showed reduced
relapse rate during ongoing RTX treatment and also prolonged
remission after cessation of RTX. However, in these studies,
different treatment regimens were employed, three of the
studies included patients with a mixture of diagnoses within
the concept of “anti-neutrophil cytoplasm antibody-associated
vasculitides” [15, 16, 18], and one study included induction
treatment as well as maintenance therapy [17]. Two review
articles on B cell depletion therapy for vasculitides have also
recently been published [19, 20].
In rheumatoid arthritis (RA), pharmacokinetic studies of
RTX have shown drug concentrations below the level of
detection, evidence of returning peripheral B cells and recur-
rence of symptoms from 24 weeks after a given RTX course
[21]. Long-term treatment with RTX (courses of 500 or
1,000 mg 2 weeks apart) repeated after 24 weeks has shown
good disease control and an acceptable safety profile in pa-
tients with RA [21].
Further knowledge about the use of RTX in patients with
GPA is essential before recommendations can be made on
maintenance treatment, including optimal dosage, and clinical
trials may reflect neither the efficacy nor the adverse reaction
rates observed in clinical practice.
This study is a retrospective analysis of actual performance
of repeated RTX cycles in a clinical setting of consecutive
GPA patients all treated at the same clinic. Based on the
positive experience of repeated treatment with RTX in RA
and the knowledge of B cell return after approximately
6 months after treatment, and as an alternative to the registered
dosing based on the lymphoma protocol suggested for induc-
tion treatment, we treated patients with severe relapsing GPA
using the RA regimen with 1,000 mg RTX 2 weeks apart
every 6 months, aiming to achieve sustainable remission. We
report efficacy and safety data from all treated patients with a
median follow-up of 32 months and longest follow-up of
111 months, suggesting this treatment regimen as a possibility
for relapsing GPA.
Patients and methods
All patients with relapses of GPA in spite of traditional
maintenance treatment and having received more than or
equal to three cycles of RTX as regularly repeated pre-
emptive maintenance therapy every 6 months between
January 2003 and February 2013 were included in the
study. The patients had to fulfil the American College of
Rheumatology criteria [22] and/or the definition of the
Chapel Hill Consensus Conference [23] for GPA. Infor-
mation on patient characteristics (sex, age at diagnosis of
GPA, duration of GPA, smoking habits), clinical manifes-
tations at diagnosis, Birmingham Vasculitis Activity Score
(BVAS) [24] at diagnosis and at follow-up, ANCA status
at diagnosis and follow-up and all treatments given before
RTX and all treatments given concomitantly with RTX, as
well as dose of other treatments including CS and of RTX
was extracted from the patient files. Information on infec-
tions and other adverse events before and after the intro-
duction of RTX and immunoglobulin (Ig) levels before
and after RTX treatment, when analysed, was likewise
collected.
Disease activity was measured using the BVAS, version 3
[24] with assessments performed 4–6 months after first and
latest RTX infusion. Remission was defined as BVAS of 0
with a dose of prednisolone of 7.5 mg or less/day, according to
EULAR recommendations [25]. Patients achieving BVAS of
0, but still on more than 7.5 mg prednisolone/day were regis-
tered as responders. Relapse was defined as a recurrence of
symptoms attributable to vasculitis plus a therapy escalation;
either unscheduled RTX, any other immunosuppressant or an
increase in CS of more than 20 mg. PR3-ANCAwas analysed
with an ELIZA kit with a cut-off value of <20 kE/l. Response
in orbital mass was defined as reduction of mass on magnetic
resonance imaging. Infections treated with antibiotics, anti-
viral therapy or anti-fungals have, in this study, been consid-
ered as “significant infections” and are included in the follow-
up.
Follow-up of RTX treatment was defined as the time from
date of first infusion until termination of follow-up (31 March
2012). Ethical approval was obtained from the regional ethics
committee.
Statistics
After Friedman ANOVA test, Wilcoxon rank test with
Bonferroni correction was used to compare changes in BVAS,
prednisolone dose and C- reactive protein (CRP) values be-
fore and after RTX treatment. Statistica version 10 was used
for statistical analyses. P values <0.05 were considered statis-
tically significant.
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Results
Patient characteristics and follow-up
The study includes 12 patients (seven females, five males) with
relapsing GPA treated with repeated cycles of RTX from Jan-
uary 2003 through February 2013. The median age at GPA
diagnosis was 44 years (range 16–61 years). The patients were
followed for a median of 32 months (range 21–111 months)
after initiation of RTX. At diagnosis, all patients were PR3-
ANCA-positive and had involvement of the upper respiratory
tract and lungs. Biopsy-proven granulomatous manifestations
were present in seven patients: three with retrobulbar granulo-
mas, two with laryngeal stenosis and two with pulmonary
granulomas. Apart from the patients with retrobulbar granulo-
ma, one further patient had CNS involvement (hypophyseal
granuloma on magnetic resonance imaging) and two had
mononeuritis. Renal manifestations included one patient with
biopsy-verified nephritis, and a further five patients with path-
ological urine sediment compatible with nephritis. All patients
had generalised disease defined as involvement of kidney and/
or lungs (Table 1).
The patients had all received CS and CY, either orally or as
repeated CY pulses, as induction therapy. Seven patients had
received induction therapy with CY more than once (median
number of treatment periods with CY 2; range 1–3), and a
majority of the patients were treated with CY over long
periods; the total median treatment time with CY was
19 months (range 2–54 months) and the median cumulative
CY dose before RTX was 61.5 g (range 11–105 g). CY was
followed by maintenance treatment with CS in all patients,
and 11 of the 12 patients had also received AZA, nine MTX,
eight MMF and four intravenous gamma-immunoglobulin.
One of the patients, with refractory GPA in spite of conven-
tional treatment including repeated CY cycles, had a bone
marrow transplant, followed by remission for 6 months. The
clinical appearance of this patient does not differ from the
other patients in the series in any other aspects, and the effect
of RTX is also comparable; for detailed characteristics of all
patients, see Table 2.
Rituximab treatment
For all patients, the main indication for pre-emptive treatment
with RTX was treatment failure with disease relapses under
ongoing conventional maintenance treatments. In addition, sev-
eral of the patients had a history of repeated and high cumula-
tive CY doses and three of the patients were young females
where the long-term negative effects of CY on fertility were
taken into account. One of the patients also experienced liver
toxicity on MTX as well as on AZA and MMF. One patient
developed necrosis of the head of femur on CS as well as liver
toxicity on AZA. The patients' median disease duration before
the initiation of RTX treatment was 35 months (range 19–270)
(mean 84 months) and the median number of relapses before
RTX was 4.0 (range 1–8). Ten of 12 patients were persistently
PR3-ANCA-positive at first RTX treatment.
The first patient was treated in 2003 with RTX according to
the lymphoma protocol (four doses of 375 mg/m2 at weekly
intervals), but thereafter, RTX treatment was given to all
patients as two infusions of 1,000 mg 2 weeks apart (with
methylprednisolone 100 mg on the day of infusion) repeated
at 6-month intervals. Four patients have been kept on this
regimen, but the dose has been lowered to 1,000 mg every
6 months in four patients, to 500mg twice 2 every 6 months in
two patients and to 500 mg once 1 every 6 months in two
patients. Reduction of the RTX dose has been done at the
discretion of the treating clinician and in all cases because
remission has been maintained. However, RTX on a pre-
emptive basis has been continued in all patients.
Table 1 Baseline characteristics of the patients with relapsing granulo-
matosis with polyangiitis (GPA) before the initiation of rituximab (RTX)
Number of patients, n 12
Gender (female/male), n (%) 7/5 (58/42)
Age at GPA diagnosis, median (range), years 46 (16–61)
Males 46 (37–61)
Females 37 (16–52)
Disease duration before RTX, median (range), months 35 (19–270)
PR3-ANCA-positive at GPA diagnosis, n (%) 12 (100)
PR3-ANCA-positive at RTX initiation, n (%) 10 (80)
Organ involvement/activity, cumulative before RTX, n (%)





Eye (keratitis, conjunctivitis) 4 (30)
Central nervous system (hypophyseal & retrobulbar
granulomas)
4 (30)
Peripheral nervous system 2 (17)
Smoker, ever, n (%) 8 (67)





Mycophenolate mofetil 8 (67)
Intravenous gammaglobulin 4 (33)
Bone marrow transplant 1 (8)
Cumulative dose cyclophosphamide before RTX,
median (range), g
61 (11–105)
ANCA anti-neutrophil cytoplasmic antibody
a Including one patient with biopsy-verified glomerulonephritis and five
with pathological urine sediment
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Rituximab treatment results
At follow-up (28 Feb 2013), a total of 75 RTX treatment
courses had been administered to the 12 patients (median six
courses/patient, range 3–13). After the first course of RTX,
four of the 12 patients (30 %) achieved remission defined as
BVAS 0 and prednisolone <7.5 mg/day, seven achieved re-
sponse (58 %) and one did not respond, according to the
definitions of remission and response used. The symptoms
and signs that remained in the eight patients who did not
achieve complete remission after the first course of RTX were
peripheral neuropathy, sensori-neural hearing deficit, arthral-
gia and pulmonary cavities. With continuous treatment, 11 of
the 12 patients (92 %) were in remission at last follow-up and
one showed clinical response (BVAS of 0 but 12.5–15 mg
prednisolone/day) (Table 2). All granulomatous manifesta-
tions responded well in two of the cases after the first treat-
ment cycle. During follow-up, only one patient experienced a
minor relapse (nasal blockage and bloody discharge, sinusitis,
rise in PR3-ANCA level from 86 to 129 kE/l). The relapse
occurred 2 months after the patient's second course of RTX
and was successfully treated with oral CS and continued RTX.
In the cohort, the median BVAS was reduced from 9 to 0
(p=0.002), median CRP from 6.0 to 2.6 (p=0.01) and 11 of 12
patients have become ANCA-negative (Table 3). The ANCA
level of the positive patient has been reduced but is still above
the cut-off value of 20 kE/l. Concerning other medications,
over time, the prednisolone dose was reduced frommedian 10
to 3.75 mg/day (p=0.003). Concomitant immunosuppressant
use has in six cases been completely omitted and has been
reduced in a further two patients. The RTX dose has been
reduced in eight patients after a median of 4.5 (range 1–6)
RTX courses of 1,000 mg twice. The patients with reduced
RTX have been followed for a median of 9 months (range 3–
38) (mean 15.6 months), so far without any disease deteriora-
tion or relapse (Table 2).
Adverse events and safety aspects
Rituximab was overall well tolerated. There were two patients
who experienced three minor infusion reactions (non-urticar-
ial rash and prurigo; occurring at infusion 1, 1 and 3, respec-
tively) which could be treated with antihistamines before
continuing the infusions.
There were seven infections that needed antibiotics, anti-
fungals or anti-viral therapy in four patients after the initiation
of RTX, (seven infections during 41 patient-years) including
one Pneumocystis jiroveci pneumonia. This is to be compared
with 14 verified infections treated with antibiotics in seven
patients before the initiation of RTX treatment (14 infections
during 79 patient-years). However, all the infections occurring
early in the disease course i.e. before RTX treatment have most
likely not been recorded as some patients were treated at other
hospitals in earlier stages of disease, which underestimates the
“background” infection incidence before RTX treatment.
Three of the four patients who developed infections after
RTXwere on concomitant steroids and other immunosuppres-
sive drugs (MTX and MMF); the forth patient has insulin-
dependent diabetes mellitus since the age of 11. The P. jiroveci
infection occurred in a young female 6 weeks after her first
RTX course, and the patient was at that time also on CS
(methylprednisolone 20 mg/day) and MTX 20 mg/week. P.
jiroveci prophylaxis was not given in conjunction with RTX
treatment as this was not routinely recommended at the time.
Smoking is known to be a risk factor for respiratory infections.
Of 14 mainly respiratory infections that occurred before RTX,
13 affected smokers and of 7 infections after RTX, 2 occurred
in smokers. Ig levels before RTX treatment were normal or
Table 3 Effect of rituximab (RTX) on disease activity, prednisolone dose and laboratory parameters
Before RTX After first RTX course Pa Last follow-up Pb
BVAS, median (range) 9 (4–15) 0.5 (0–6) 0.002 0 (0–0) 0.002
Prednisolone dose (mg/day), median (range) 10.0 (0–18) 8.8 (0–20) ns 3.75 (0–15) 0.003
CRP, mg/l, median (range) 6.0 (0.3–96) 4.9 (0.3–53) ns 2.6 (0.3–9.2) 0.01
Remission, n (%) 0 3 (25) 11 (92)
Response, n (%) 8 (67) 1 (8)
No response, n (%) 1 (8) 0 (0)
Immunoglobulin levelsc
IgG g/l, median (range) 8.98 (5.4–15.1) 6.81 (4.1–10.5)
Ig A g/l, median (range) 1.85 (0.87–3.5) 1.52 (0.78–3.3)
IgM g/l, median (range) 0.81 (0.23–1.7) 0.54 (0.2–1.3)
BVAS Birmingham Vasculitis Activity Score [22], ns non-significant
a Comparison before RTX and after first RTX course
b Comparison before RTX and at last follow-up
cMeasured at variable time points after the start of RTX, reference values: IgG, 6.7–14.5 g/l; IgA, 0.88–4.5 g/l; IgM, 0.27–2.1 g/l
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just below normal (three patients had IgG and one patient IgA
just under reference level). Information on Ig levels after RTX
was retrieved and related to the total dose of RTX that each
patient had received at the time point of Ig testing (Tables 2
and 3). The three patients who had received the highest doses
of RTX also had the lowest IgG and IgM levels. Among the
four patients who had infections during follow-up, two had
subnormal Ig levels (IgG and IgG+IgM, respectively).
B cell levels have not beenmeasured in all patients as this is
not recommended in routine care. As expected, B cell levels
were undetectable in those who were tested after RTX admin-
istration (three patients). All patients were screened negative
for hepatitis B before RTX treatment was initiated and there
were no cases of hepatitis B after the start of RTX.
Discussion
Untreated GPA is a disease with high mortality and morbidity.
The current well-established therapeutic options (mainly CY in
combination with CS) achieve high rates of remission, but the
problem of relapsing disease and treatment toxicity remains.
RTX is now approved in the USA as well as in Europe for
induction treatment ofGPA andMPA,with a recommended dose
of 375 mg/m2 given once weekly for 4 weeks. There are no
recommendations on maintenance therapy or concomitant im-
munosuppressive treatment. In this case series of 12 patients with
relapsing GPA in routine clinical care, we report efficient and
well-tolerated maintenance treatment with repeated pre-emptive
RTX infusions given every 6 months, a regimen which has
proven effective in RA. The patients have received a median of
six RTX treatment courses (range 3–13) with amedian total dose
of 9,000 mg RTX (range 6,000–21,500 mg), and during a
median follow-up period of 32 months (range 21–111 months),
11 of the 12 patients (92 %) have achieved and maintained
remission, 1 has achieved response (stable BVAS of 0 but
prednisolone 12.5–15 mg/d) and only 1 patient has had a
(minor) relapse during follow-up.
These results support those previously reported for ANCA-
associated vasculitides by Rhee et al. [15] and Roubaud-
Bauldron et al. [16] and are consistent with the recently
published, larger studies by Cartin-Ceba et al. [17] and Smith
et al. [18], although patient characteristics and treatment reg-
imens partly differ between the studies. In the study by Smith
et al., RTX dosage was 1,000 mg every 6 months in one
treatment arm (similar to the regime in our study), but in this
study, RTX was discontinued after 24 months in all patients.
Three of the previous studies include patients with GPA as
well as MPA [15, 16, 18], which represent two different
diseases [26] making evaluation of treatment results difficult
as response to treatment may differ between the diseases.
Generally, the patients in our study seem to have a more
severe and long-standing disease than those in the previous
studies. In the study by Rhee et al., the patients had a median
BVAS of 1, and in the Cartin-Ceba study, the median BVASwas
5 at RTX initiation. The patients in the Smith study (groupB) had
received a median dose of 14.9 g CY and the median disease
duration was 43 months compared to our study where median
BVAS was 9, the median cumulative CY dose was 61 g and the
median disease duration was 35 months (mean 84 months). In
the present study, there was no difference in effect of RTX on
granulomatous and vasculitic disease manifestations. This is in
contrast to the previous study where granulomatous manifesta-
tions, especially orbital masses, responded less well than vas-
culitic manifestations to a regimen of RTX as four doses of
375 mg/m2 at weekly intervals [11].
Apart from different doses and dose intervals for RTX in
previous studies, also strategies for co-medication have dif-
fered. In one study, all immunosuppressive agents were stopped
and CS dose reduced at start of RTX [18]. In another study, CS
at a dosage of 1 mg/kg/day was introduced at RTX initiation
followed by stepwise reduction of CS [17]. In our study
reflecting clinical routine, RTX was added to the ongoing
maintenance therapy of immunosuppressants and CS when
relapse occurred. In patients who achieved stable remission,
concomitant immunosuppressive drugs were omitted or re-
duced and CS was tapered at the discretion of the treating
physicians. Notably, with this regimen, only four of the 12
patients obtained remission after the first course of RTX and
repeated courses were needed for the majority of patients to
achieve andmaintain remission. Achieving disease control with
RTX enabled reduction or withdrawal of other immunosup-
pressive drugs (Table 2). In the FDA and EMA, approval of
RTX for GPA suggested dosages are copied from the lympho-
ma protocol. Our study supports that a regimen with 1,000 mg
twice every 6 months is efficient and well tolerated and that
RTX doses can be reduced over time. Optimal dosage and dose
intervals of RTX need to be further investigated, but possibly
according to our preliminary results and others, dosing of RTX
can be reduced once stable remission has been achieved. In
seven of the patients in this study, the RTX dose was reduced
without relapses occurring, but follow-up is still short (median
9 months; mean 15.6 months). In one of the previously men-
tioned studies [18], an initial course of 1,000 mg RTX 2 weeks
apart was followed by a single dose of 1,000 mg RTX every
6 months for a total of 24 months reporting a relapse rate of
12 % over 2 years. Comparisons between studies regarding
optimal RTX regimen are however hampered by the differences
in study populations and study designs.
Biomarkers, in particular B cell levels and ANCA titres,
have been suggested to be used to predict relapse and guide
retreatment with RTX, but studies have been conflicting, and
so far there is little support for the use of these markers to
guide optimal time point for retreatment with RTX. No con-
clusions regarding biomarkers can be drawn from this study,
but it can be noted that the only patient with a relapse had a
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persistently increased ANCA level. B cell levels and determi-
nation of CD 19+ cells (as a possible measure of disease
activity) have not been consistently analysed, as this is not
standard of routine.
As infections have been reported in previous trials on RTX,
we made special effort to scrutinise the medical files to find all
infections in the patients before and after the initiation of RTX
treatment. Despite this, information about infections in patients
treated at other hospitals in earlier stages of disease may have
been missed, and infection incidence before RTX is therefore
probably underestimated. In our study, there were 17 significant
infections/100 patient-years during follow-up after the start of
RTX, and although this figure was similar to 18 reported
significant infections/100 patient-years before RTX, this mate-
rial does not allow us to make exact conclusions about infection
risks before and after RTX. The number of infections requiring
treatment with antibiotics, anti-fungal or anti-viral therapy is
still small (seven infections in 4 of the 12 patients after RTX).
There was one opportunistic infection (P. jiroveci pneumonia)
which occurred after the first RTX treatment with a concomitant
relatively high dose of CS. At this time, prophylaxis for P.
jiroveci was not given, but is now recommended by the FDA
and EMA for patients with GPA treated with RTX, andwe have
changed our routines accordingly. Infections were not consis-
tently correlated to low immunoglobulin levels (Table 2).
Smoking did not emerge as a main predisposing risk factor
for infections during RTX treatment in these patients. None of
the patients developed late-onset neutropenia previously report-
ed in patients with RA, SLE and vasculitis receiving RTX [27],
neither have we experienced progressive multifocal leukoence-
phalopathy (only previously reported in patients with RA and
SLE receiving RTX [28]). The infection rate after RTX was
considerably higher in our patient group than that reported for
RA patients (4.3/100 patient-years), treated with similar RTX
treatment regimen [29]. However, and as was evident in our
study, it is plausible that the background infection risk in GPA
in general is higher than in RA because of the systemic nature
of the disease, damage of upper and lower airways predisposing
for airway pathogens and the immunosuppressive treatments,
including CY, given over time. This emphasises that pattern and
incidence of adverse events in RTX-treated GPA patients may
differ from what is reported in other RTX-treated patient
groups.
The strength of this study lies in the setting in normal
clinical practice and in the relatively long follow-up time, also
that the patients have been followed at the same clinic with
easily accessible and comprehensive electronic medical files
for follow-up. The initial treatment regimen has been consis-
tent, and all patients with GPA treated with repeated RTX
infusions at our clinic have been included, which eliminates
any risk of selection bias.
However, there are several limitations to our study, mainly
the small study population and the retrospective design, hence
the heterogeneity in treatments given before start of RTX. Also,
the patients initially continued previous immunosuppressive
drugs during RTX treatment, and concomitant medications
have been gradually withdrawn, which may also influence
relapse rate. The relatively low age in the population may have
influenced the infection risk. Follow-up time is too short to
yield information on possible delayed unexpected effects of
long-term B cell depletion and the possible late effects of
hypogammaglobulinemia seen in some patients. The role for
concomitant immunosuppressive treatment is still unclear. Pos-
sibly, continuing MTX or AZA may allow for a regimen with
RTX given at lower dose or greater interval, reducing the risk of
hypogammaglobulinemia. On the other hand, reduced doses of
CS and other immunosuppressive drugs most likely have long-
term beneficial effects on infection risks.
In conclusion, this study adds to our knowledge on RTX as
maintenance treatment in patients with severe, relapsing GPA
and indicates that RTX, given pre-emptively every 6 months
as initially described in RA, can prevent relapses, allows for
reduction of concomitant immunosuppressive drugs and CS
and is well tolerated under a median observation period of
32 months. Extended studies are needed to further establish
the place of RTX in maintenance therapy and the role of
concomitant immunosuppression.
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